Clinical Trials on Cystic Fibrosis and Non CF Bronchiectasis

Total 1819 results

Liminal BioSciences Ltd.

Terminated

Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance

Cystic Fibrosis

Canada
University of Miami
University of Alabama at Birmingham; University of Kansas Medical Center; Children... and other collaborators

Terminated

Losartan and Inflammation in Cystic Fibrosis

Cystic Fibrosis

United States
Pharmaxis
ethica Clinical Research Inc.; Europe: KasaConsult bvba, Hoegaarden, Belgium; Argentina: Resolution Latin America; Buenos Aires, Argentina

Completed

Long Term Administration of Inhaled Mannitol in Cystic Fibrosis

Cystic Fibrosis

United States, France, Belgium, Canada, Argentina, Germany, Netherlands
MemorialCare Health System
University of California, Irvine

Completed

Impact of Telerehabilitation Training on Pediatric Cystic Fibrosis Patients: An Exploratory Study

Cystic Fibrosis

United States
Hannover Medical School
Heidelberg University; University of Giessen

Completed

ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor (OrkambiFacts)

Cystic Fibrosis

Germany
Insmed Incorporated

Completed

Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)

Cystic Fibrosis

Poland, Ukraine, Serbia, Belgium, Hungary, Slovakia, North Macedonia
AO GENERIUM

Completed

Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis

Fibrosis | Cystic Fibrosis

Russian Federation
University Hospital, Bordeaux

Unknown

Polyethylene Glycol and Intestinal Inflammation in Cystic Fibrosis (MUCOLAX)

Cystic Fibrosis
Koronis Biomedical Technologies
Johns Hopkins University

Unknown

Cystic Fibrosis Remote Monitoring System

Cystic Fibrosis
University of Alabama at Birmingham
Cystic Fibrosis Foundation

Completed

A Two-Part Multicenter Prospective Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis (PROSPECT) (PROSPECT)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

United States, Belgium, Netherlands, United Kingdom, Canada, Germany, Australia, France, Italy, Czechia, Austria, Greece, Sweden
PTC Therapeutics
Cystic Fibrosis Foundation; ECFS-Clinical Trial Network (ECFS-CTN)

Completed

Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)

Cystic Fibrosis

United States, Spain, United Kingdom, Netherlands, Germany, France, Belgium, Italy, Australia, Argentina, Brazil, Bulgaria, Canada, Greece, Israel, Poland
Proteostasis Therapeutics, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United Kingdom
Proteostasis Therapeutics, Inc.

Completed

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background Therapy

Cystic Fibrosis

United Kingdom
King's College Hospital NHS Trust
King's College London

Completed

LBM & Lung Function in Adolescents With CF

Cystic Fibrosis

United Kingdom
Queen Mary University of London

Completed

Air Pollution and Children With Cystic Fibrosis

Cystic Fibrosis

United Kingdom
University Hospital, Montpellier

Completed

Educational Program Through Video Conference for Inhaled Therapies in Cystic Fibrosis Patients (Visio-Respir)

Cystic Fibrosis

France
Pontificia Universidade Católica do Rio Grande...

Completed

Interactive Video Game Responses in Cystic Fibrosis (Igamecf)

Cystic Fibrosis

Brazil
Children's Hospital of Philadelphia

Completed

Nasal Potential Difference (NPD) for the Diagnosis of Cystic Fibrosis

Cystic Fibrosis

United States
Imperial College London
University of Pennsylvania; University of Oxford; University of Edinburgh; Royal... and other collaborators

Completed

Single Dose of pGM169/GL67A in CF Patients

Cystic Fibrosis

United Kingdom
Vertex Pharmaceuticals Incorporated

Approved for marketing

VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)

Cystic Fibrosis
Cigdem Emirza
Istanbul University

Completed

Effects of Expiratory Muscle Training on Cough Efficacy in Children and Adolescents With Cystic Fibrosis

Cystic Fibrosis

Turkey
Assistance Publique - Hôpitaux de Paris
Vaincre la Mucoviscidose

Completed

Comparison of Non-invasive Measurement Methods of Hepatic Fibrosis in Cystic Fibrosis (MUCO-FIBRO)

Cystic Fibrosis

France
Augusta University

Completed

Cystic Fibrosis and Endothelial Function: At Rest and During Exercise

Cystic Fibrosis

United States
Hospices Civils de Lyon

Completed

Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF) (OMEGAMUCO)

Cystic Fibrosis
Nationwide Children's Hospital
Genentech, Inc.

Completed

Effectiveness of Pulmozyme in Infants With Cystic Fibrosis

Cystic Fibrosis

United States
Galapagos NV

Completed

A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis. (FALCON)

Cystic Fibrosis

Belgium, Bulgaria, Germany, Greece, Netherlands, Serbia, Sweden, United Kingdom
Hospices Civils de Lyon

Completed

Gynecological Health Improvement of Adult Women With Cystic Fibrosis (IMPACT)

Cystic Fibrosis
Heart of England NHS Trust
University of Birmingham; National Institute for Health Research, United Kingdom

Completed

A Study of Home Monitoring in Adults With Cystic Fibrosis (HOMECF) (HOME-CF)

Cystic Fibrosis

United Kingdom
University Hospitals Cleveland Medical Center
Cystic Fibrosis Foundation

Completed

Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation

Cystic Fibrosis

United States
Papworth Hospital NHS Foundation Trust
University of Sheffield

Suspended

Hyperpolarized Xenon Imaging in Patients With Cystic Fibrosis

Cystic Fibrosis

United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

Cystic Fibrosis

United States, Australia, Canada, United Kingdom, Germany, Belgium, Austria, Ireland, Italy, France
University of Texas Southwestern Medical Center
Genentech, Inc.

Withdrawn

Metabolic Abnormalities in Hispanic Children With Cystic Fibrosis

Cystic Fibrosis

United States
University of Southern California

Completed

Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis

Cystic Fibrosis

United States
Tim Corcoran

Completed

Repeatability and Response Study of Absorptive Clearance Scans

Cystic Fibrosis

United States
Marmara University

Completed

Clinical Effects of Exercise Program Added to Pulmonary Rehabilitation in Patients With Cystic Fibrosis

Cystic Fibrosis

Turkey
The Hospital for Sick Children

Completed

18FDG-PET Imaging to Detect Changes in Airways Inflammation in Cystic Fibrosis Patients

Cystic Fibrosis

Canada
Medical University of South Carolina
Vertex Pharmaceuticals Incorporated

Completed

An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations

Cystic Fibrosis
University Childrens' Hospital (Zentrum für Kinderheilkunde...
University of Bonn; University Hospital Frankfurt

Unknown

Effect of Azithromycin on Fatty Acids in CF

Cystic Fibrosis
University of Colorado, Denver
Cystic Fibrosis Foundation

Terminated

Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation

Cystic Fibrosis

United States, Australia, Canada, Germany, Switzerland, Israel, Netherlands, Belgium, Italy, United Kingdom, France
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada, France, Spain, Israel, Australia, Austria
University of Colorado, Denver

Completed

Outpatient Antibiotic Treatment for a Cystic Fibrosis Pulmonary Exacerbation

Cystic Fibrosis

United States
Stanford University

Terminated

Controlled Ventilation CT in CF Infants

Cystic Fibrosis

United States
AlgiPharma AS
Eurostars; Smerud Medical Research International AS

Completed

A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis (SMR-2984)

Cystic Fibrosis

United Kingdom, Denmark, Norway, Germany, Sweden
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

Cystic Fibrosis

United States, Canada, Germany, United Kingdom
Unity Health Toronto

Completed

HFN Versus NIV in Cystic Fibrosis. The HIFEN Study

Cystic Fibrosis

Canada
Corbus Pharmaceuticals Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis

Cystic Fibrosis

Belgium, United States, United Kingdom, Italy, France, Germany, Poland
Horizon Pharma USA, Inc.

Completed

"Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"

Cystic Fibrosis

United States
Joseph Pilewski
Cystic Fibrosis Foundation

Completed

Effects of Inhaled Bicarbonate on Airway pH in Cystic Fibrosis

Cystic Fibrosis

United States

Clinical Trials on Cystic Fibrosis and Non CF Bronchiectasis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations